patent.fyi
Applications  /  US 2026/0355167
United States Patent Application Publication

US 2026/0355167 A1

Published
Nov 12, 2026
Filed
Apr 24, 2026
Earliest date on the face
Apr 25, 2025
Classification
A61K 31/4418
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Porous titanium reservoir

What ifWhat if a rigid reservoir meters drug release through a porous metal outlet?
Claim language“a bioerodible polymeric matrix”

A titanium housing holds the inhibitor in a cavity that opens to the vitreous through a sintered titanium disk. Dissolved drug diffuses through the disk, with its thickness and pore structure controlling the diffusion rate.

1.1Active site binding antibody

What ifWhat if an antibody fragment inhibits plasma kallikrein by blocking substrate access to its active site?
Claim language“avoralstat or a pharmaceutically acceptable salt thereof”

An erodible hydrogel holds the antibody fragment and releases it as the network swells and its crosslinks hydrolyze. The released fragment binds near the enzyme's active site and reduces cleavage of high molecular weight kininogen.

1.2Drug pellet inside sleeve

What ifWhat if the inhibitor forms a discrete pellet in the cavity of an erodible polymer sleeve?
Claim language“dispersed within the bioerodible polymeric matrix”

A pressed pellet of crystalline inhibitor sits inside a hollow polymer sleeve with a small opening at one end. Vitreous fluid enters through the opening, dissolves drug at the exposed pellet face, and carries dissolved drug out by diffusion.

1.2Separate drug and polymer layers

What ifWhat if the inhibitor forms a separate solid layer between two erodible polymer sheets?
Claim language“dispersed within the bioerodible polymeric matrix”

A compacted drug layer sits between two drug-free polymer sheets, with its perimeter exposed to vitreous fluid. The fluid dissolves drug at the perimeter, and erosion of the sheets exposes additional drug surface.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Intravitreal implant for veterinary retinal studies

A bioerodible rod containing dispersed avoralstat is placed in the vitreous of a rabbit for a veterinary ophthalmology study. An intravitreal applicator deposits the rod, and serial ocular imaging records its position and dimensions. Vitreous samples collected at scheduled endpoints provide avoralstat concentrations for comparison with the measured change in rod dimensions.

Component substitution

Polyanhydride matrix for surface erosion

A copolymer of sebacic acid and 1,3-bis(p-carboxyphenoxy)propane forms the drug-bearing matrix. Dry avoralstat particles are blended with the copolymer powder and compression molded into a rod. Hydrolysis of anhydride bonds at the wetted surface exposes the dispersed drug as the rod erodes.

Parameter or scale variation

Equal mass rods with different diameters

A single blend containing 40 percent avoralstat by mass is molded into two cylindrical geometries for bench testing. One rod measures 0.30 mm in diameter by 4.0 mm in length, and the other measures 0.60 mm in diameter by 1.0 mm in length. The two geometries have equal nominal volume at the same molded density, and the narrower rod has greater exposed surface area. Both rods are immersed separately in identical release media to measure the effect of geometry on release.

Rod with a radial drug gradient

Concentric extrusion forms a rod with a 0.30 mm core and a 0.60 mm overall diameter. Both streams contain the same bioerodible polymer, with avoralstat dispersed at 40 percent by mass in the core and 10 percent by mass in the surrounding layer. The continuous outer layer places less drug at the cylindrical surface and increases the diffusion distance from the core to that surface. Water ingress and matrix erosion change that diffusion path during release.

Combination with existing systems

Implant preloaded in a trocar applicator

A rod containing avoralstat dispersed in a bioerodible polymer sits in the distal lumen of a single-use intravitreal trocar applicator. The lumen bore exceeds the maximum rod diameter, and a retractable distal stop retains the rod during handling. After insertion, a thumb actuator withdraws the stop and advances a coaxial push rod to discharge the implant into the vitreous.

Automated or data-driven variant

Automated flow through release testing

A mesh cradle holds the implant in a temperature-controlled flow cell while a metering pump passes buffered medium over it. A software-controlled valve directs the outlet into successive collection vials at programmed intervals. Liquid chromatography measures avoralstat in each fraction, and software multiplies each concentration by the collected volume and sums the masses to produce a cumulative release profile.

Specific version of a part

Lactide glycolide copolymer matrix

A copolymer with a 50:50 molar ratio of lactide to glycolide forms a solid matrix containing avoralstat. Water penetrates the matrix and hydrolyzes its ester bonds, reducing polymer molecular weight and contributing to drug release.

Crystals distributed by extrusion

Micronized avoralstat crystals are dry blended with polymer powder and distributed through the softened polymer by screw extrusion below the drug's melting point. The extruded strand cools and is cut into implant lengths.

Drug dispersion by solvent casting

Avoralstat and the erodible polymer dissolve in a common volatile solvent, and the solution is cast into a shallow mold. Solvent evaporation and vacuum drying leave the drug distributed through the solid film, which is cut into implant strips.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2015/0140062 A1
Published
May 21, 2015
Filed
Nov 14, 2014
Class
A61K 9/204
Document BUS 2022/0160694 A1
Published
May 26, 2022
Filed
Apr 8, 2020
Class
A61K 31/4418
Claim 1
Document A
Document B
1.1a bioerodible polymeric matrix and a plasma kallikrein (PKal) inhibitor selected from avoralstat or a pharmaceutically acceptable salt thereof
In some embodiments, the plasma kallikrein inhibitor is avoralstat.
B · US 2022/0160694 A1 · ¶ 147
1.2wherein the PKal inhibitor is dispersed within the bioerodible polymeric matrix.
A method for treating diabetic macular edema (DME), the method comprising injecting a bioerodible implant into the vitreous of a human at a frequency of once every about six months to once every about nine months, the bioerodible implant comprising a continuous, double extruded rod comprising dexamethasone homogeneously dispersed within a biodegradable polymer matrix; wherein the biodegradable polymer matrix comprises a mixture of poly(D,L-lactide-co-glycolide) (PLGA) having
A · US 2015/0140062 A1 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, these treatment options have some drawbacks and do not work effectively for all patients.
A · US 2015/0140062 A1 · ¶ 9
The present disclosure is concerned with and directed to implants and methods for the treatment of an ocular condition, such as macular edema, including diabetic macular edema (“DME”).
A · US 2015/0140062 A1 · ¶ 10
However, even for this mode of administration the half-life of many drugs is such that repeated injections are required (for example every 1 to 2 months) and the concentration of the drug is below the levels needed for effective treatment.
B · US 2022/0160694 A1 · ¶ 3
In some embodiments, the method for treating an ocular disease or condition in a subject in need thereof comprising non-surgically administering a drug composition comprising an effective amount of a compound of the disclosure to the SCS of the eye of the subject provides a favorable ocular PK profile (for example, an increased concentration of the compound of the disclosure in the SCS or an ocular tissue).
B · US 2022/0160694 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0355167 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355167/, SHA-256 ac11cd4f19eb9ee5eca18232477e2d5144207776b7e3df960e3d718dea211114
First published
Permanent addresshttps://patent.fyi/US20260355167/
Content fingerprint (SHA-256)ac11cd4f19eb9ee5eca18232477e2d5144207776b7e3df960e3d718dea211114
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi